154 related articles for article (PubMed ID: 33322687)
1. The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations.
Luong AB; Do HQ; Tarchi P; Bonazza D; Bottin C; Cabral LKD; Tran LDC; Doan TPT; Crocè LS; Pham HLT; Tiribelli C; Sukowati CHC
Cells; 2020 Dec; 9(12):. PubMed ID: 33322687
[TBL] [Abstract][Full Text] [Related]
2. miR-589-5p inhibits MAP3K8 and suppresses CD90
Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
[TBL] [Abstract][Full Text] [Related]
3. miR-125a/b inhibits tumor-associated macrophages mediated in cancer stem cells of hepatocellular carcinoma by targeting CD90.
Wang Y; Wang B; Xiao S; Li Y; Chen Q
J Cell Biochem; 2019 Mar; 120(3):3046-3055. PubMed ID: 30536969
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection.
Zhao RC; Zhou J; Chen KF; Gong J; Liu J; He JY; Guan P; Li B; Qin Y
Neoplasma; 2016; 63(2):288-98. PubMed ID: 26674131
[TBL] [Abstract][Full Text] [Related]
6. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study.
Sukowati CH; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
PLoS One; 2013; 8(10):e76830. PubMed ID: 24116172
[TBL] [Abstract][Full Text] [Related]
7. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of liver cancer stem cells by RNA-sequencing.
Ho DW; Yang ZF; Yi K; Lam CT; Ng MN; Yu WC; Lau J; Wan T; Wang X; Yan Z; Liu H; Zhang Y; Fan ST
PLoS One; 2012; 7(5):e37159. PubMed ID: 22606345
[TBL] [Abstract][Full Text] [Related]
9. The Expressions of CD44, CD90 and Alpha Fetoprotein Biomarkers in Indonesian Patients with Advanced Liver Disease: an Observational Study.
Mustika S; Wijaya H; Pratomo B
Acta Med Indones; 2019 Apr; 51(2):137-144. PubMed ID: 31383828
[TBL] [Abstract][Full Text] [Related]
10. Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma.
Cheng SW; Tsai HW; Lin YJ; Cheng PN; Chang YC; Yen CJ; Huang HP; Chuang YP; Chang TT; Lee CT; Chao A; Chou CY; Chan SH; Chow NH; Ho CL
PLoS One; 2013; 8(11):e80053. PubMed ID: 24244607
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90.
Yoshida M; Yamashita T; Okada H; Oishi N; Nio K; Hayashi T; Nomura Y; Hayashi T; Asahina Y; Ohwada M; Sunagozaka H; Takatori H; Colombo F; Porretti L; Honda M; Kaneko S
Sci Rep; 2017 Sep; 7(1):11292. PubMed ID: 28900199
[TBL] [Abstract][Full Text] [Related]
12. Differential capacity of CD90+ cells in autophagy activation following chemotherapy in hepatocellular carcinoma.
Do HQ; Luong AB; Bonazza D; Bottin C; Doan TP; Tran LD; Truong NH; Tell G; Pham HL; Tiribelli C; Sukowati CH
Ann Hepatol; 2020; 19(6):645-652. PubMed ID: 32745631
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma.
Lingala S; Cui YY; Chen X; Ruebner BH; Qian XF; Zern MA; Wu J
Exp Mol Pathol; 2010 Aug; 89(1):27-35. PubMed ID: 20511115
[TBL] [Abstract][Full Text] [Related]
14. Expression of Cancer Stem Cell-associated
Sakabe T; Azumi J; Umekita Y; Toriguchi K; Hatano E; Hirooka Y; Shiota G
Anticancer Res; 2017 Sep; 37(9):4881-4888. PubMed ID: 28870909
[TBL] [Abstract][Full Text] [Related]
15. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.
Kim BH; Park JW; Kim JS; Lee SK; Hong EK
Gut Liver; 2019 May; 13(3):342-348. PubMed ID: 30600675
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells.
Liu Z; Dai X; Wang T; Zhang C; Zhang W; Zhang W; Zhang Q; Wu K; Liu F; Liu Y; Wu J
Cancer Lett; 2017 Aug; 400():149-160. PubMed ID: 28455240
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
[TBL] [Abstract][Full Text] [Related]
18. Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation.
Hwang HS; Yoo JE; Han DH; Choi JS; Lee JG; Joo DJ; Kim MS; Kim SI; Choi GH; Park YN
Gut Liver; 2022 May; 16(3):443-455. PubMed ID: 34737243
[TBL] [Abstract][Full Text] [Related]
19. CAF-induced placental growth factor facilitates neoangiogenesis in hepatocellular carcinoma.
Liu Z; Chen M; Zhao R; Huang Y; Liu F; Li B; Qin Y
Acta Biochim Biophys Sin (Shanghai); 2020 Jan; 52(1):18-25. PubMed ID: 31828297
[TBL] [Abstract][Full Text] [Related]
20. [Plasma sB7-H3 serves as an assistant diagnostic marker for hepatitis B virus-associated hepatocellular carcinoma].
Xu W; Li F; Yu L; Liu J; He X; Fan R; Chen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):744-7. PubMed ID: 25001942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
